1 Case Studies in Modeling and Simulation Discussion Stella G. Machado, Ph.D. Office of Biostatistics/OTS/CDER/FDA FDA/Industry Workshop, September 2006.

Slides:



Advertisements
Similar presentations
Equivalence Tests in Clinical Trials
Advertisements

What is Pharmacometrics (PM)?
Matthew M. Riggs, Ph.D. metrum research group LLC
Applying Multilevel Models in Evaluation of Bioequivalence in Drug Trials Min Yang Prof of Medical Statistics Nottingham Clinical Trials Unit School of.
Correlation & the Coefficient of Determination
Hypothesis Testing Goal: Make statement(s) regarding unknown population parameter values based on sample data Elements of a hypothesis test: Null hypothesis.
Robert T. O’Neill, Ph.D. Director, Office of Biostatistics CDER, FDA
Monte Carlo simulations and bioequivalence of antimicrobial drugs NATIONAL VETERINARY S C H O O L T O U L O U S E July 2005 Didier Concordet.
Statistical vs. Practical Significance
Development of Evaluation and Consultation on Bridging Studies: Thailand Experiences Suchart Chongprasert, Ph.D. Investigational New Drug Subdivision Food.
Module 16: One-sample t-tests and Confidence Intervals
1.What is Pearson’s coefficient of correlation? 2.What proportion of the variation in SAT scores is explained by variation in class sizes? 3.What is the.
Objectives 10.1 Simple linear regression
Inference for Regression
Regression Analysis Once a linear relationship is defined, the independent variable can be used to forecast the dependent variable. Y ^ = bo + bX bo is.
Correlation and regression
Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,
Objectives (BPS chapter 24)
Estimation and Reporting of Heterogeneity of Treatment Effects in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare.
Chapter 13 Multiple Regression
Lecture 23: Tues., Dec. 2 Today: Thursday:
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
Chapter 12 Multiple Regression
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Data Freshman Clinic II. Overview n Populations and Samples n Presentation n Tables and Figures n Central Tendency n Variability n Confidence Intervals.
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
1 Equivalence and Bioequivalence: Frequentist and Bayesian views on sample size Mike Campbell ScHARR CHEBS FOCUS fortnight 1/04/03.
Lecture 19: Tues., Nov. 11th R-squared (8.6.1) Review
Variability Measures of spread of scores range: highest - lowest standard deviation: average difference from mean variance: average squared difference.
Business Statistics - QBM117 Interval estimation for the slope and y-intercept Hypothesis tests for regression.
Independent Sample T-test Often used with experimental designs N subjects are randomly assigned to two groups (Control * Treatment). After treatment, the.
Introduction to Probability and Statistics Linear Regression and Correlation.
Inferences About Process Quality
Clinical Pharmacology Overview From the Antiviral Perspective Kellie Schoolar Reynolds, Pharm.D. Pharmacokinetics Team Leader Office of Clinical Pharmacology.
Charge to the Committee Kimberly Struble, Pharm.D. Regulatory Review Officer Division of Antiviral Drug Products.
Exercise 6 Dose linearity and dose proportionality
Assessing Survival: Cox Proportional Hazards Model Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.
WHO Prequalification Program Workshop, Kiev, Ukraine, June 25-27,2007.
Qian H. Li, Lawrence Yu, Donald Schuirmann, Stella Machado, Yi Tsong
Simple Linear Regression Models
Assessing Survival: Cox Proportional Hazards Model
Simple Linear Regression One reason for assessing correlation is to identify a variable that could be used to predict another variable If that is your.
ACPS Meeting, October 19-20, 2004 BioINequivalence: Concept and Definition Lawrence X. Yu, Ph. D. Director for Science Office of Generic Drugs, OPS, CDER,
Elementary Statistics Correlation and Regression.
Biostatistics Class 6 Hypothesis Testing: One-Sample Inference 2/29/2000.
Multiple Regression and Model Building Chapter 15 Copyright © 2014 by The McGraw-Hill Companies, Inc. All rights reserved.McGraw-Hill/Irwin.
Inference for Regression Simple Linear Regression IPS Chapter 10.1 © 2009 W.H. Freeman and Company.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
Statistical considerations Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.
Examining Relationships in Quantitative Research
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
2006, Tianjin, China sf.ppt - Faragalli 1 Statistical Hypotheses and Methods in Clinical Trials with Active Control Non-inferiority Design Yong-Cheng.
1 METHODS FOR DETERMINING SIMILARITY OF EXPOSURE-RESPONSE BETWEEN PEDIATRIC AND ADULT POPULATIONS Stella G. Machado, Ph.D. Quantitative Methods and Research.
 Chapter 3! 1. UNIT 7 VOCABULARY – CHAPTERS 3 & 14 2.
Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,
Course: Research in Biomedicine and Health III Seminar 5: Critical assessment of evidence.
Bioequivalence Criteria Research Plan Stella G. Machado, Ph.D. Office of Biostatistics and the Replicate Design Technical Committee Advisory Committee.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 Current Status of Dose Selection in Antimicrobial Drug Development.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT Ramana S. Uppoor, R.Ph., Ph.D. Division of Clinical Pharmacology-1 Office of Clinical Pharmacology, CDER, FDA.
Methods to Adjust Doses Based on Exposure-Response Information Points to Consider Richard Lalonde Clinical Pharmacokinetics and Pharmacodynamics Pfizer.
REGRESSION (R2).
Stats Club Marnie Brennan
Chapter 12: Comparing Independent Means
Graphing Techniques.
Hypothesis tests in linear regression
Yang Liu, Anne Chain, Rebecca Wrishko,
Assessing similarity of curves: An application in assessing similarity between pediatric and adult exposure-response curves July 31, 2019 Yodit Seifu,
Presentation transcript:

1 Case Studies in Modeling and Simulation Discussion Stella G. Machado, Ph.D. Office of Biostatistics/OTS/CDER/FDA FDA/Industry Workshop, September 2006

2 Regulatory issue Approval was sought for monotherapy for pediatric population, without another clinical trial Clinical trial data for Drug X: –Adults: adjunct and monotherapy –Pediatric population: adjunct PK/PD modeling used for bridging the adjunct therapy data (data masked)

3 Bridging PK/PD Studies General method comparing PK/PD response curves in: Pediatric versus Adult populations Different Regions Exposure: dose, AUC, Cmin, etc Response: biomarkers, clinical endpoints Goal is to evaluate similarity in PK/PD relationships between 2 populations Conclude: similarity, similarity with some dose regimen modification; lack of similarity

4 DRUG X: PK/PD scatter plot with loess fits

5 STEPS IN THE STATISTICAL APPROACH assess similarity between responses at all concentrations likely to be encountered account for variability of the response need Equivalence type approach, not hypothesis tests showing that the responses are not significantly different analysis is more exploratory than confirmatory

6 Steps Usual equivalence-type analysis: –similarity defined as requirement that average responses in the 2 populations, at the same C, are closely similar: –choose reference goalposts L and U, eg 80% to 125% –calculate 95% confidence interval for ratio of average responses ( 1 / 0 ) for all C

7 EXAMPLE: Drug X Response transformed by square root to stabilize the variance Linear models fitted separately for the two populations: sqrt(response) = a + b * Conc+ For each C, 5000 pairs of studies generated 5000 estimates of 1 / 0, and percentiles

8 DRUG X: 95% CIs for ratios 1 / 0 for concentrations: 0, 20,50,70,90 via model-based method

9 Remarks for example Response higher for pediatric population for concentrations above 50mg =>Shows lack of similarity, but dose adjustment would be possible if high concentrations are called for Limits of (80, 125) might not be medically most sensible for interpretation in each situation